Key facts
- Brenus Pharma’s last known valuation is $45.4M.
- It has raised $30.0M; the latest was Later Stage VC ($23.9M) in Jul 2024.
- Notable investors include Creative Destruction Lab, Bpifrance, UI Investissement, Noshaq, Crédit Agricole Centre France Développement — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Brenus Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Brenus Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brenus Pharma
Developer of anti-cancer cell-based immunotherapy designed to generate allogeneic cell vaccines for solid tumors. The company platform empowers immune cells in vivo to fight cancer through two core mechanisms: mimicking cancer nature and making it visible to the immune system. The company's therapy educates the immune system to anticipate relapse mechanisms by stimulation of selected tumor cell lines, enabling oncologists to induce response during treatment with chemotherapy or radiotherapy.
- Sector
- Healthcare
- HQ
- Issoire, France
- Founded
- 2014
- Employees
- 14
- Website
- brenus-pharma.com/
- Ownership
- Privately Held (backing)
Brenus Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brenus Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brenus Pharma in its N-PORT filings yet. We sweep new filings monthly.